In recent years, advancements in diagnostic imaging modalities, such as cardiac magnetic resonance (CMR) and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET), as well as the accumulation of cases, have allowed a more accurate diagnosis of cardiac sarcoidosis (CS). In addition, emerging cases of "isolated CS" in which no obvious lesions are present in organs other than the heart have been reported, and the clinical importance of CS has become recognized. Many issues including etiology, pathology, diagnosis, and treatment of CS remain to be solved. Considering this situation, guidelines for the diagnosis and treatment of cardiac sarcoidosis were recently updated by the Japanese Circulation Society and were published in February 2017.
Diagnostic guidelines for cardiac sarcoidosis
There have been only a few guidelines that address how to diagnose and treat CS. Many healthcare professionals have In the updated guidelines for the diagnosis and treatment of CS, the JCS has further revised criteria for cardiac Annals of Nuclear Cardiology Vol. (Table 2 ). Guidelines on diagnosing isolated CS were also created (6) ( Table 3) .
New feature of the updated CS guidelines
Criteria for cardiac involvement were revised from the 2006 version in the following ways: 1) Fatal ventricular arrhythmia 
Importance of imaging modalities
As epithelioid granulomas in CS develop sporadically in the myocardium, it has been reported that only 20% of patients with epithelioid granulomas can be correctly diagnosed with an EMB because biopsy samples do not contain granulomatous tissues. The low sensitivity of EMB in CS may be partly due to preferential location of myocardial injury in the mid- Cardiac findings should be assessed based on the major criteria and the minor criteria. Clinical findings that satisfy the following 1) or 2) strongly suggest the presence of cardiac involvement. 1) Two or more of the five major criteria (a) to (e) are satisfied . 2) One of the five major criteria (a) to (e) and two or more of the three minor criteria (f) to (h) are satisfied.
(Note: English translation of tables has been provided by the authors.) Table 2 Diagnostic guidelines for cardiac sarcoidosis 1) Histological diagnosis group (those with positive myocardial biopsy findings) Cardiac sarcoidosis is diagnosed histologically when endomyocardial biopsy or surgical specimens demonstrate non-caseating epithelioid granulomas.
2) Clinical diagnosis group (those with negative myocardial biopsy findings or those not undergoing myocardial biopsy)
The patient is clinically diagnosed as having sarcoidosis (1) when epithelioid granulomas are found in organs other than the heart, and clinical findings strongly suggestive of the above-mentioned cardiac involvement (Table 1) are present; or (2) when the patient shows clinical findings strongly suggestive of pulmonary or ophthalmic sarcoidosis; at least two of the five characteristic laboratory findings of sarcoidosis (Table 4) ; and clinical findings strongly suggest the above-mentioned cardiac involvement (Table 1) .
(Note: English translation of tables has been provided by the authors.) layer or epicardial layer rather than endocardial layer that is suggested by LGE on cardiac magnetic resonance (CMR).
As the positive detection rate in EMB is much lower in patients with normal heart function, a correct histological diagnosis is difficult to make in patients at an early stage of CS. However, it is critically important to diagnose the disease at an early stage to ensure effective treatment and positive outcomes.
In this regard, reliable, precise clinical diagnostic criteria must be established without delay. As currently there are no specific biomarkers available to diagnose CS, clinicians place expectations on imaging modalities such as CMR and 18 F-FDG PET. CMR has good spatial resolution enough to discern the location of LGE not only horizontal distribution but also vertical involvement of myocardial layer. Although only LGE is included in the criteria for cardiac involvement, the usefulness of T2 weighted imaging and T1 mapping should be investigated in the future. Significant positive tracer accumulation with 18 F-FDG PET is listed in the characteristic laboratory findings associated with sarcoidosis (Table 4 ).
These findings reflect the active inflammation in sarcoidosis and are useful in evaluating treatment efficacy. In the past few years, many studies have shown the diagnostic utility of 18 F-FDG PET in patients with CS, and evaluation involving 18 F-FDG PET is therefore included as an important component in the "Criteria for cardiac involvement of sarcoidosis" (Table 1) and in the "Diagnostic guidelines for isolated cardiac sarcoidosis" (Table 3) . While 18 F-FDG PET is considered mandatory by the clinical diagnosis group, it has been pointed out that physiological 18 F-FDG uptake in the myocardium should be prevented in order to make a correct diagnosis, and specific points regarding its use have also been noted (3) .
Further improvements to and advancements in imaging modalities are being sought to ensure timely and accurate diagnosis of CS.
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